Related Experiment Video
Updated: Sep 1, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
Giant cell myocarditis following COVID-19 successfully treated by immunosuppressive therapy
Afsaneh Amiri1, Golnaz Houshmand1, Sepideh Taghavi1
1Rajaie Cardiovascular Medical and Research Center School of medicine, Iran University of Medical Sciences Tehran Iran.
Insights
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause heart failure. This case report details a patient successfully treated for COVID-19-related heart failure with immunosuppressive therapy.
Area of Science:
- Cardiology
- Infectious Diseases
- Immunology
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, causing coronavirus disease 2019 (COVID-19), is linked to multi-organ impairment, including cardiac and immunological complications.
- Acute myocarditis is a recognized severe complication of COVID-19.
Observation:
- A 46-year-old female with a history of lichen planus dermatitis experienced rapidly progressive heart failure following a COVID-19 infection.
- Endomyocardial biopsy results were consistent with giant cell myocarditis (GCM).
Findings:
- The patient's heart failure was diagnosed as GCM post-COVID-19.
- Successful treatment was achieved using a combination immunosuppressive therapy regimen.
Implications:
- This case highlights a rare but serious cardiac complication of COVID-19.
- Immunosuppressive therapy may be an effective treatment for GCM in the context of COVID-19.
- Further research into the immunological mechanisms of COVID-19-induced myocarditis is warranted.
Abstract:
It has been shown that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by coronavirus disease 2019 (COVID-19), can lead to multi-organ impairment including cardiac involvement and immunological problems. Acute myocarditis is one of serious and fatal complications of COVID-19. In this case report, we present a 46-year-old lady with a history of lichen planus dermatitis who has developed a rapidly progressive heart failure after an episode of COVID-19. The pathologic examination of her endomyocardial biopsy specimens was compatible with GCM, and she was successfully treated with a combined immunosuppressive therapy regimen.
More Related Videos
09:11Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
07:50Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Cardiomyopathy V: Interprofessional Care
Pericarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis I: Introduction